top of page

Corbus Pharmaceuticals posts positive result on its antibody drug study

Corbus Pharmaceuticals has recently reported positive results from its first-in-human study of CRB-701, a key antibody drug. The company's shares have surged significantly following this news, with an increase of over 300% and 256% in different reports. The positive data from the trial, which demonstrated strong safety and efficacy in tackling certain tumors, has generated enthusiasm and optimism among investors. The company's CEO has also noted that CRB-701 appears to be superior to other options in its ability to treat, suggesting meaningful benefits for patients and the company. This development has positioned Corbus Pharmaceuticals as a high-potential biotech player, and the market has responded with strong momentum. The company's press releases and additional details can be found on its official website.

8 views0 comments

Recent Posts

See All

Comments


bottom of page